Therapeutic high-dose vitamin D for vitamin D-deficient severe COVID-19 disease: randomized, double-blind, placebo-controlled study (SHADE-S)
- 30 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Public Health
- Vol. 46 (2) , 256-266
Abstract
Efficacy of therapeutic cholecalciferol supplementation for severe COVID-19 is sparingly studied. effect of single high-dose cholecalciferol supplementation on sequential organ failure assessment (SOFA) score in moderate-to-severe COVID-19. participants with moderate to severe COVID-19 with PaO2/FiO2 ratio < 200 were randomized to 0.6 million IU cholecalciferol oral (intervention) or placebo. primary outcome was change in Day 7 SOFA score and pre-specified secondary outcomes were SOFA and 28-day all-cause mortality. in all, 90 patients (45 each group) were included for intention-to-treat analysis. 25(OH)D3 levels were 12 (10–16) and 13 (12–18) ng/ml (P = 0.06) at baseline; and 60 (55–65) ng/ml and 4 (1–7) ng/ml by Day 7 in vitamin D and placebo groups, respectively. The SOFA score on Day 7 was better in the vitamin D group [3 (95% CI, 2–5) versus 5 (95% CI, 3–7), P = 0.01, intergroup difference − 2 (95% CI, −4 to −0.01); r = 0.4]. A lower all-cause 28-day mortality [24% compared to 44% (P = 0.046)] was observed with vitamin D. single high-dose oral cholecalciferol supplementation on ICU admission can improve SOFA score at Day 7 and reduce in-hospital mortality in vitamin D-deficient COVID-19. ClinicalTrials.govid: NCT04952857 registered dated 7 July 2021. What is already known on this topic—vitamin D has immunomodulatory role. Observational and isolated intervention studies show some benefit in COVID-19. Targeted therapeutic vitamin D supplementation improve outcomes in severe COVID-19 is not studied in RCTs. What this study adds—high-dose vitamin D supplementation (0.6 Million IU) to increase 25(OH)D > 50 ng/ml is safe and reduces sequential organ failure assessment score, in-hospital mortality in moderate to severe COVID-19. How this study might affect research, practice or policy—vitamin D supplementation in vitamin D-deficient patients with severe COVID-19 is useful may be practiced.Keywords
This publication has 26 references indexed in Scilit:
- MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19European Journal of Endocrinology, 2020
- “Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”The Journal of Steroid Biochemistry and Molecular Biology, 2020
- Cytomegalovirus Infection Downregulates Vitamin D Receptor in Patients Undergoing Hematopoietic Stem Cell TransplantationTransplantation, 2020
- The SOFA score—development, utility and challenges of accurate assessment in clinical trialsCritical Care, 2019
- Hepatitis B virus downregulates vitamin D receptor levels in hepatoma cell lines, thereby preventing vitamin D-dependent inhibition of viral transcription and productionMolecular Medicine, 2018
- Autophagy, apoptosis, vitamin D, and vitamin D receptor in hepatocellular carcinoma associated with hepatitis C virusMedicine, 2018
- Human cytomegalovirus infection downregulates vitamin-D receptor in mammalian cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2017
- Effect of a Single Oral Dose of 600,000 IU of Cholecalciferol on Serum Calciotropic Hormones in Young Subjects with Vitamin D Deficiency: A Prospective Intervention StudyThe Journal of Clinical Endocrinology & Metabolism, 2010
- Epstein-Barr virus encoded EBNA-3 binds to vitamin D receptor and blocks activation of its target genesCellular and Molecular Life Sciences, 2010
- Short and Long-Term Variations in Serum Calciotropic Hormones after a Single Very Large Dose of Ergocalciferol (Vitamin D2) or Cholecalciferol (Vitamin D3) in the ElderlyThe Journal of Clinical Endocrinology & Metabolism, 2008